AzTrials
AzTrials

Abdominal PainPhase 3GR-CWINCT02002663

Continuous Local Anesthetic and Steroid Infusion in Abdominal Surgery

A Phase 3 study testing ropivacaine 0.2%, Methylprednisolone 1mg/kg and saline 0.9% in people with Abdominal Pain, run by Fondazione IRCCS Policlinico San Matteo di Pavia at 2 sites in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the study is the identification, comparing continuous infusion of local anesthetics and steroids intralesionally with the current gold standard therapy (PCA), of the effective dose of local anesthetics and steroids within 7 days following abdominal surgery in order to halve the consumption of opioids and… Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Abdominal Pain
What is being tested?
ropivacaine 0.2%, Methylprednisolone 1mg/kg and saline 0.9%
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
2 sitesItaly
Study dates
Aug 2013to Sep 2016
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male and females 18-85 years old scheduled to use PCA with morphine for postoperative pain control
  • HIV-negative
  • Classification American Society of Anesthesiologists (ASA) I: without systemic disease
  • Classification ASA II or III (moderate systemic disease or severe systemic disease that limits activity without disability)
  • Scheduled for major abdominal and urologic surgery (no emergency surgery)

Who cannot join

  • regular use of opioid analgesics;
  • History of abuse of drugs and / or alcohol;
  • Postoperative hospitalization in intensive care with sedation and / or mechanical ventilation;
  • severe renal impairment (creatinine> 2 g / dl, creatinine clearance <30 ml / h) and / or hepatic impairment (cholinesterase <2000 IU);
  • Cardiac disorders (arrhythmias, heart failure);
  • Neurological disorders (epilepsy);
Show all 12Show fewer
  • Cognitive disorders, mental retardation, psychiatric disorders;
  • Changes in the normal coagulation or coagulopathy (INR> 2, PTT> 44 sec);
  • Platelet count less than 100.000/mm3;
  • BMI> 30;
  • Allergy to study drugs.
  • diabetes type I/II

Trial locations and contacts

2 sites in 1 country.

Italy2 sites
  • •2nd Service of Anesthesia, Intensive Care and Pain Therapy, University Hospital of Parma

    Parma, 43126

  • Department of Anesthesia and ICU, General Surgery and Urology, S Matteo Hospital

    Pavia, 27100

Other trials in Italy

About this study

Official title: Efficacy of the Intralesional Infusion of Local Anesthetic and Steroids After Major Abdominal Surgery: a Randomized Double Blind Phase III Trial

The aim of the study is the identification, comparing continuous infusion of local anesthetics and steroids intralesionally with the current gold standard therapy (PCA), of the effective dose of local anesthetics and steroids within 7 days following abdominal surgery in order to halve the consumption of opioids and give the best pain control with a lower incidence of side effects and persistent chronic pain (at 1 and 3 months) We also plan to measure the peripheral inflammation and oxidative stress by analyzing the pro-inflammatory cytokines and anti-inflammatory properties.

Another objective is to investigate the combined effect of polymorphisms of genes related to pain sensitivity, and the correlation with the development of the inflammatory response and the incidence of chronic post-surgical pain (CPSP), which will be considered to validate the genotype-phenotype correlations.

Read more

The intralesional catheter will be placed within the operating field by the surgeon at the end of the procedure.

  • first postoperative 24 hours: ropivacaine 0.2%-methylprednisolone 1 mg/kg/die infusion (10ml/h) in the wound. Rescue dose with morphine via intravenous PCA (0.5 mg/ml, bolus 1 mg, lock-out 5 min, max 20 mg in 4 hours)
  • from 24 hs to 48 hs: ropivacaine 0.2%-methylprednisolone 1 mg/kg/die infusion (10ml/h) or saline 0.9% 10 ml/h in the wound. Rescue dose with morphine via intravenous PCA (0.5 mg/ml, bolus 1 mg, lock-out 5 min, max 20 mg in 4 hours) . from 48 hs to 7th day: ropivacaine 0.2% or saline 0.9% via patient controlled intralesional analgesia (PCIA) (2 mg/ml, bolus 20 mg, lock-out 60 min, max 80 mg in 4 hours). Rescue dose Tramadol 100 mg.

The first assessment will be by the anesthetist pre-operatively, to verify the patient eligibility.

All patients will be evaluated at the end of surgery (T0) and after 3-6-12-24-36-48 hours after surgery. Further evaluations are scheduled every 24 hours until the seventh postoperative day. At each assessment will be recorded: Numeric Rating Scale (NRS) at rest, NRS at movement (NRSm) - defined as pain at deep inspiration and cough - ; blood pressure, heart rate, respiratory rate, nausea (PONV scale), need of rescue analgesics and presence of any complications.

On the 7th postoperative day, the patient will be reassessed by both pain clinicians and surgeon; the surgeon will remove the catheter.

At 1 month and 3 months after surgery, the patient will be evaluated through phone interview to investigate pain persistence.

Inflammatory response analysis will be performed on the first 15 patients in each group (for a total of 30 patients). Before awakening of the patient the surgeon will insert a microdialysis catheter in the fat adjacent to the surgical wound with sterile technique. The microdialysed liquid will be collected in dedicated tubes directly in the infusion pump. The sample of the first hour will be discarded to avoid that microtrauma of catheter positioning influences the study. Sampling will be performed every 6 hours the first day, and every 12 hours in the second and third day. Serum samples will be collected to compare systemic with regional samples. All samples will be stored at -80 ° C until sampling. Concentrations quantification of different cytokines will be analyzed by ELISA Parma Unit will analyze VNTR (variable number of tandem repeats) polymorphism of the ADRB2 gene, directly related to the risk of chronic persistent postoperative pain development; Pavia Unit will take care of genotyping of polymorphic sites in the following genes: OPRM1 (mu-opioid receptor 1), COMT (catecholamine O-methyl transferase), UGT2B7 (UDP-glucuronyl transferase), IL1Ra (interleukin 1receptor alpha). From the blood samples will be extracted DNA and RNA using standard procedures. RNA will be retained for possible future studies on the expression of genes of interest. The DNA will be used instead for the study of genetic polymorphisms.

In this study the formation of free radicals, particularly superoxide will be assessed together with lipid peroxidation in both serum and urine, The 8- deoxyguanosine and Poly-ADP-ribose polymerase (PARP), the presence of nitrotyrosine.

Blood samples and urine tests will be carried out before the start of surgery , before the bolus of morphine and local anesthetic , at 24 h after the end of the intervention and 48 h after end of the intervention

Conditions
Abdominal Pain
Being tested
ropivacaine 0.2%, Methylprednisolone 1mg/kg, saline 0.9%
Medical subject headings
Abdominal Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ropivacaine 0.2%Drug

    Also called morphine PCA

    PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs

  • Methylprednisolone 1mg/kgDrug

  • saline 0.9%Drug

Study groups in NCT02002663
Study groupRoleWhat they receive
ropivacaine + methylprednisoloneExperimentalContinuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
Receives: Drug: ropivacaine 0.2%; Drug: Methylprednisolone 1mg/kg
salinePlacebo comparatorContinuous infusion of saline through intralesional catheter for 24 hs
Receives: Drug: saline 0.9%

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. total morphine consumption

    Measured: 7 days after surgery

Secondary outcomes (4)
  1. pain values

    number of patients presenting NRS values lower than 4 both at rest and at movement

    Measured: 7 days

  2. number of patients presenting methylprednisolone side effects

    wound healing retardation or other side effects which could be related to steroid wound infusion

    Measured: up to 7 days

  3. number of patients presenting morphine or ropivacaine side effects

    incidence of PONV, pruritus and sedation; side effects related to local anesthetic's systemic absorption

    Measured: up to 7 days

  4. persistent pain at 1 and 3 months

    number of participants developing pain at 1 and 3 months after surgery

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2013 (estimated)
  2. Study startAug 2013
  3. Primary completionJun 2016
  4. Study completionSep 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02002663
Sponsor's protocol ID
PT-SM-13- YR FIRST STEP CWI-PP
Acronym
GR-CWI
Status last verified
Mar 2017
First submitted
24 Oct 2013
Last updated
3 Mar 2017
Results posted
No
Data monitoring committee
Yes

Publications

  • Bugada D, De Gregori M, Compagnone C, Muscoli C, Raimondi F, Bettinelli S, Avanzini MA, Cobianchi L, Peloso A, Baciarello M, Dagostino C, Giancotti LA, Ilari S, Lauro F, Grimaldi S, Tasciotti E, Fini M, Saccani Jotti GM, Meschi T, Fanelli G, Allegri M. Continuous wound infusion of local anesthetic and steroid after major abdominal surgery: study protocol for a randomized controlled trial. Trials. 2015 Aug 14;16:357. doi: 10.1186/s13063-015-0874-z.

    PubMed 26272452

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing ropivacaine 0.2%, Methylprednisolone 1mg/kg and saline 0.9% in people with Abdominal Pain, run by Fondazione IRCCS Policlinico San Matteo di Pavia at 2 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

total morphine consumption (time frame: 7 days after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02002663, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in